Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | LATS1 |
| Gene Name: | LATS1 |
| Protein Full Name: | Serine/threonine-protein kinase LATS1 |
| Alias: | EC 2.7.11.1; Large tumor suppressor 1; LATS, large tumor suppressor, 1; WARTS |
| Mass (Da): | 126870 |
| Number AA: | 1130 |
| UniProt ID: | O95835 |
| Locus ID: | 9113 |
| COSMIC ID: | LATS1 |
| Gene location on chromosome: | 6q25.1 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBIT |
| Number of cancer specimens: | 19535 |
| Percent of cancer specimens with mutations: | 0.26 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | Yes |
| Normal role description: | LATS1 is a protein serine/threonine kinase that suppresses tumour progression by restricting proliferation and promoting apoptosis by activating the transcription of BAX, caspase 3 and p53. It can phosphorylate and inactivate the YAP1 oncoprotein and inhibit its translocation to the nucleus for transcription of genes important for proliferation and migration. LATS1 also negatively regulates the G2/M transition by downregulating CDK1 kinase activity. M669I and R806P mutations have been associated with lung adenocarcinoma and lung large cell carcinoma, respectively. Decreased LATS1 expression due to hypermethylation of the promoter have been associated with breast cancer, acute lymphoblastic leukemia, ovarian cancer, and astrocytoma. |